Merger Expected to Close Today 80% of Shares Tendered Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”) today announced the successful completion of the tender offer (the...
Endo Merger Agreement with NuPathe Terminated -- Endo congratulates NuPathe on negotiating an improved agreement with Teva and accepts termination fee PR Newswire MALVERN, Pa., Jan. 21, 2014...
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc. (Nasdaq:PATH) for $3.65 per share...
NuPathe Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover PR Newswire DALLAS, Jan. 17, 2014 DALLAS, Jan. 17, 2014 /PRNewswire/ -- Securities lawyers at Deans & Lyons...
Lifshitz Law Firm Announces Investigation of Coleman Cable, Inc., NuPathe Inc., Solta Medical, Inc., The Jones Group Inc. and Tufco Technologies, Inc. PR Newswire NEW YORK, Dec. 30, 2013 NEW...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NuPathe, Inc. Juan E. Monteverde, a partner at...
INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation of NUPATHE INC. and Its Board of Directors In Connection with the Sale of the Company to Endo Health Solutions -- PATH PR...
Harwood Feffer LLP Announces Investigation of NuPathe, Inc. PR Newswire NEW YORK, Dec. 17, 2013 NEW YORK, Dec. 17, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating...
The law firm of Wohl & Fruchter LLP is investigating the acquisition of NuPathe, Inc. (NuPathe) (Nasdaq:PATH) by Endo Health Solutions Inc. (Endo). On December 16, 2013, NuPathe...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of NuPathe, Inc. (“NuPathe” or the “Company”) (Nasdaq:PATH) relating...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관